The Kidney Disease Improving Global Outcomes (KDIGO) as well as the American Diabetes Association (ADA) guidelines have recommended the use of ACE inhibitors and ARBs for patients with DKD to reduce blood pressure and to achieve ≥30% reduction in albuminuria [363,364,365]. This evidence concerns the gene ACE and diabetic kidney disease.